Diabetic Treatment Centers of America Announces Letter of Intent to Acquire Movement Disorder Technologies
Posted on: Tuesday, 22 February 2005, 18:00 CST
Diabetic Treatment Centers of America Inc. (OTCBB: DBTC) announced today the execution of a Letter of Intent to acquire Movement Disorder Technologies Inc.
"Movement Disorder Technologies (MDT) has an outstanding team that has a proven history of developing significant medical devices. Providing neurologists with technology that will assist in the treatment of Parkinson's disease, Essential Tremor, and Tourette's Syndrome will dramatically increase the size of the market for Diabetic Treatment Centers of America," said Arden Oliphant, CEO of Diabetic Treatment Centers of America Inc.
"We look forward to working with Diabetic Treatment Centers of America to leverage our technologies and provide a means to better health to those who suffer with movement disorders," said Carl L. Doane, EVP of Movement Disorder Technologies.
The Letter of Intent, which was executed by both parties, provides for the negotiation of the final terms, is non-binding on both parties and subject to the completion of due diligence considered normal and customary in transactions of this type.
About Diabetic Treatment Centers of America
Based in Salt Lake City, DTC of America is dedicated to providing effective medical therapies to diabetics that will significantly improve their health and well-being.
Safe Harbor Statement
This news release may include forward-looking statements within the meaning of Section 27a of the United States Securities Act of 1933, as amended, and Section 21e of the United States Securities and Exchange Act of 1934, as amended, with respect to achieving corporate objectives, developing additional project interests, the company's analysis of opportunities in the acquisition and development of various project interests and certain other matters. These statements are made under the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements contained herein.
Source: Business Wire
Related Articles
- Center for Autism and Related Disorders Study Finds Hyperbaric Oxygen Therapy Ineffective Treatment for Children with Autism
- Jacksonville's Medical and Tourism Industries Unite As America's Health Center
- Lipomics Technologies to Partner With Joslin Diabetes Center in Insulin Resistance Research
- Diabetes Centers of America Becomes Diabetes America
- University of Advancing Technology Designated As a Center of Academic Excellence By National Security Agency and Department of Homeland Security
- Against the Backdrop of an Accelerating Diabetes Epidemic, Joslin Diabetes Center Launches $100 Million Fundraising Campaign; Largest Campaign in Center's History to Expand Research, Clinical and Education Programs
- Cytomedix Announces Preliminary Results of Clinical Trial for Treatment of Diabetic Foot Ulcers
- Keryx Biopharmaceuticals, Inc. Initiates Pivotal Phase 3 and Phase 4 Clinical Program of KRX-101 for Treatment of Diabetic Nephropathy
- FDA Approves Levemir(R) (Insulin Detemir [rDNA Origin] Injection) - a New, Long-Acting Insulin Treatment for Diabetes
- Insmed Announces Expansion of Patent Portfolio in the Treatment of Diabetes; New European Patent Granted for SomatoKine
 |
 |
User Comments (0)
RSS Feeds